DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG
published in: Neuro-Oncology
date of publication: 2019-04-23
Cites articles
There is nothing here
Article - wd:Q94331729